Pfizer Inc. (PFE) reported better-than-expected earnings for the third quarter of 2018 but missed estimates on revenues, causing the stock to fall 2.8% during premarket hours on Tuesday. Total revenues of $13.3 billion were up 1% from the same period last year, driven by growth of key brands such as Eliquis, Ibrance, Xeljanz, Prevnar 13 … Continue reading Pfizer’s stock drops after Q3 revenue misses estimates despite earnings beat